solengepras Parkinson's disease program
phase 3drug program · high · Tue May 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Reduce motor complications and OFF-time in Parkinson's disease, including motor fluctuations and early untreated Parkinson's disease motor and non-motor features.
Once-daily oral small-molecule GPR6 inverse agonist evaluated in randomized placebo-controlled clinical trials, including a pivotal Phase 3 ARISE trial.
Pivotal Phase 3 ARISE trial enrollment completed; topline data expected at the end of Q3 2026.
Phase 2 trial assessed CVN424 as adjunctive treatment to levodopa for reducing OFF-time in Parkinson's disease patients with motor fluctuations; no efficacy results were provided in the supplied material.
Brain-penetrant CD38 inhibitor program
preclinicaldrug program · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Support development of next-generation brain-penetrant CD38 inhibitors for neurodegenerative diseases and age-associated cognitive decline by elevating NAD+ through CD38 inhibition.
Structure-guided optimization of small-molecule CD38 inhibitors and X-ray crystal structure analysis of the CVN14-ADPR-CD38 complex.
2026 publication identified CVN14 as a potent, selective, brain-penetrant tool molecule suitable for advanced preclinical evaluation.
CVN14 had favorable pharmacokinetic properties and enabled disclosure of a high-resolution crystal structure showing an uncompetitive binding mode.
GPR6 thermogenesis and weight-management research program
exploratoryresearch program · medium · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify and validate a CNS target for weight management by increasing energy expenditure without suppressing appetite.
Transcriptomic profiling, in situ hybridization, high-throughput drug screening, and metabolic phenotyping in diet-induced obese male mice; intervention with a potent and highly selective GPR6 inverse agonist.
2026 Nature Communications publication identified GPR6-enriched DRN/vlPAG GABAergic neurons as a thermogenic target for weight management in mice.
GPR6 inverse agonism significantly prevented weight gain in male mice on a high-fat diet by stimulating brown adipose tissue thermogenesis without affecting appetite.
NETSseq platform
exploratoryplatform · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify novel drug targets and cell type-specific disease mechanisms in the human brain for neurodegenerative, psychiatric, and CNS-controlled metabolic disorders.
Proprietary Nuclear Enriched Transcript Sort sequencing platform for cell type-specific transcriptomic profiling of human brain tissue.
2025 publication applied NETSseq to ataxia-telangiectasia cerebellar tissue and reported inflammatory and aging mechanisms in distinct cell types.
NETSseq found neurotransmitter signaling dysregulation in granule neurons and accelerated aging signatures in astrocytes and microglia, with stronger low-abundance gene detection and lower cross-contamination than single-nuclei technologies.
CVN293 THIK-1 inhibitor program
preclinicaldrug program · high · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a brain-permeable KCNK13/THIK-1 inhibitor for clinical assessment, with therapeutic rationale around microglia-specific control of neuroinflammation.
Small-molecule inhibition of THIK-1/KCNK13; human brain microglia electrophysiology, inflammatory signaling assays, and nuclear sequencing evidence support target biology.
Cerevance published discovery of CVN293 as a brain-permeable KCNK13/THIK-1 inhibitor suitable for clinical assessment in 2024.
Blocking THIK-1 strongly suppressed ATP-evoked IL-1β release in human microglia, supporting THIK-1 inhibition as a microglia-specific strategy to contain neuroinflammation.
CVN766 orexin 1 receptor antagonist program
phase 1drug program · high · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat schizophrenia and related psychiatric conditions through selective orexin 1 receptor antagonism.
Potent small-molecule orexin 1 receptor antagonist evaluated in a randomized, double-blind, placebo-controlled single- and multiple-ascending-dose Phase 1 study in healthy volunteers.
Publication in 2024 disclosed CVN766 and stated the candidate is being investigated in clinical trials for schizophrenia and related psychiatric conditions.
CVN766 showed greater than 1000-fold selectivity for orexin 1 over orexin 2 receptor, low off-target hits, good brain permeability, and target occupancy in preclinical characterization.
CVN058 schizophrenia target-engagement program
phase 1drug program · high · Fri Nov 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate pharmacodynamic target engagement in people with schizophrenia using mismatch negativity as a downstream marker of 5-HT3 receptor modulation.
Phase 1 double-blind, placebo-controlled, three-period crossover clinical study measuring auditory evoked potential mismatch negativity downstream of 5-hydroxytryptamine receptor 3.
Phase 1 clinical trial record published for CVN058 target engagement in schizophrenia.
